3Q EARNINGS: Allergan lists options, omits Valeant
This article was originally published in Scrip
Executive Summary
Allergan reported another quarter of double-digit sales and earnings growth on 27 October, and the company outlined three additional means for increasing shareholder value, but none of the options included an acquisition by Allergan's dogged pursuer Valeant Pharmaceuticals.